Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 5/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 3/20 | 0.42 |
| ▸ | XIAP | P98170 | 2/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.40 |
| ▸ | CASP2 | P42575 | 2/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.40 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16468657 | 0.88 | ACE (0.50) | CALCRLRENCASP3CASP2 | |
| SCHEMBL30525434 | 0.88 | CALCRL (0.50) | CALCRLSLC6A2XIAPCAPN1REN | |
| SCHEMBL30525445 | 0.85 | CAPN1 (0.53) | CALCRLSLC6A2XIAPCAPN1CMA1 | |
| SCHEMBL30401176 | 0.85 | SLC6A2 (0.49) | CALCRLSLC6A2XIAPCAPN1REN | |
| SCHEMBL3084259 | 0.84 | CALCRL (0.41) | CALCRLCASP3CASP2 | |
| SCHEMBL29521253 | 0.83 | CALCRL (0.49) | CALCRLXIAPCAPN1REN | |
| SCHEMBL5065494 | 0.82 | XIAP (0.48) | CALCRLSLC6A2ELANEXIAPCAPN1 | |
| SCHEMBL5065490 | 0.82 | XIAP (0.48) | CALCRLSLC6A2ELANEXIAPCAPN1 | |
| SCHEMBL29575852 | 0.82 | CMA1 (0.51) | CALCRLSLC6A2ELANEXIAPCAPN1 | |
| SCHEMBL30532203 | 0.81 | CALCRL (0.45) | CALCRLSLC6A2XIAPCAPN1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166063-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | CALCRL 2145/4885SLC6A2 1505/4885ELANE 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.